Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total non-GAAP adjustments before income taxes ($M) ($M)
Form 8-K Non-GAAP Adjustment Summary
Latest, FY2025
2,720
Period ended Dec 31, 2025
Change on a year earlier
-61.9%
7,132 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total non-GAAP adjustments before income taxes ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,720 | -61.9% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 7,132 | +134.1% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | 3,046 | -44.7% | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 5,507 | +78.7% | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 3,082 | -66.9% | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 9,300 | +89.8% | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
| FY2019 | Dec 31, 2019 | 4,900 | +58.3% | Form 8-K (exhibit991earningspressrel.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 3,096 | +60.8% | Form 8-K (exhibit991earningspres.htm, filed 2020-02-04) ↗ |
| FY2017 | Dec 31, 2017 | 1,925 | -19.8% | Form 8-K (exhibit991earningspressrel.htm, filed 2019-02-04) ↗ |
| FY2016 | Dec 31, 2016 | 2,400 | – | Form 8-K (gildq42017exh991.htm, filed 2018-02-06) ↗ |
Breakdown
What makes up total non-gaap adjustments before income taxes ($m)
- Total non-GAAP adjustments to costs and expenses ($M)3,171 · FY2025
- Non-GAAP R&D adjustments ($M)112 · FY2025
- Non-GAAP other income (expense) adjustments (equity securities fair value, $M)-451 · FY2025
- Income tax effect of non-GAAP adjustments ($M)-647 · FY2025
- Discrete and related tax charges (benefits) ($M)353 · FY2025
- Total non-GAAP adjustments after tax ($M)1,719 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Total non-GAAP adjustments before income taxes ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng_adj_pretax
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.